中国上市公司协会联合中国基金报等媒体，开展 " 我在 ' 十四五 ' 这五年，上市公司在行动 " 主题宣传活动。日前，记者走进重庆太极实 业（集团）股份有限公司（以下简称太极集团或公司，股票代码： 600129.SH ），多方位了解 " 十四五 " 期间太极集团在推动中医药产 业高质量发展中的创新与坚守。 见习记者 荧墨 战略引领：锚定 " 世界一流的中药企业 " 愿景 " 十四五 " 期间，太极集团提出 " 做世界一流的中药企业 " 的企业愿 景，确立 " 关爱生命 呵护健康 " 的企业理念，心怀 " 国药泽华 夏， 太极济苍生 " 的企业使命。 " 在战略方向上，公司聚焦 '4+1' 重点产品管线，加大中药大品种二次开发及中药创新药研发，并通过全产业链数字化转型升级，不断提 升现代中药智能制造水平。 " 太极集团向记者表示， 在中医药传承创新方面，太极集团树立了 " 正源出新 精益求精 " 的企业核心价值 观，提出 " 三源三新 " 理念。 " 三源三新 " 即正中华文明之源、正中医文化之源、正中药本草之源，创新产品形态、创新产出业态、创新产业生态，推动中医药现代化 和国际化。 关于 " 正源 " ，太极 ...

Group 1 - The 2025 China International Service Trade Fair will be held from September 10 to 14, focusing on health and wellness services with the theme "Smart Leading Future, Healthy Life" [1] - The health and wellness service section will feature two main display experience areas: "Smart Therapy Cloud Matrix" and "National Health Service Matrix" [1] - Major global companies such as Elsevier and GE Healthcare will participate, with a participation rate of 54% from Fortune 500 companies and 53% internationalization rate [1] Group 2 - The Health Priority Zone will showcase innovative projects from local medical institutions, focusing on the integration of medical and elderly care services [2] - A record 48 traditional Chinese medicine institutions will participate, with 27 offline, highlighting the modernization and international potential of traditional Chinese medicine [2] - The Capital International Medical Conference will take place during the trade fair, discussing technology innovation and the development of the medical and health industry [3]

Core Insights - The company is advancing its strategic layout and business progress through product pipeline expansion, technological innovation, and industrial collaboration, showcasing strong resilience and growth potential [1] Group 1: Product Innovation and Core Competitiveness - The company has been upgrading its product pipeline and increasing R&D investment, with its subsidiary obtaining approval for 16 chemical drug listings, covering major diseases with significant market potential [2] - The introduction of AI visual inspection technology for production monitoring and the development of a smart trading platform for traditional Chinese medicine (TCM) are enhancing the company's competitive edge [2] Group 2: Industry Ecosystem Development - The company is promoting industrial cooperation projects to boost local economic development, linking over 10,000 quality herbal merchants through its trading center [3] - A strategic partnership with a leading TCM company has strengthened the supply capacity of herbal medicines, enhancing the trading center's competitiveness [3] Group 3: Digital Transformation and Supply Chain Management - The company initiated the Guizhou Shennong Valley project to create a standardized, digitalized, and networked industry ecosystem, establishing 6 standardized planting bases covering 4,400 acres [4] - The implementation of a digital management platform ensures traceability and quality control of herbal medicines, benefiting both product quality and farmer income [4] Group 4: Brand Empowerment and Market Expansion - The company has developed a comprehensive marketing system to enhance brand influence, showcasing its diverse product pipeline at national trade events [5] - Core products have excelled in national TCM procurement, reinforcing market position through quality advantages and innovative strategies [5] Group 5: Sustainable Development Strategy - The company has proposed a dual-engine strategy focusing on "scientific innovation and resource aggregation," aiming to enhance evidence-based medicine research and smart manufacturing [6] - The goal is to modernize and internationalize traditional Chinese medicine, targeting a marketing scale of 10 billion and creating a health industry ecosystem [6] Group 6: Overall Growth Path - The company demonstrates a clear growth trajectory and momentum through strategic focus, product innovation, and ecosystem collaboration, addressing market concerns amid regulatory challenges [7][8]

Core Viewpoint - The collaboration between Jinan University and Zhongjing Wanshi Pharmaceutical aims to conduct clinical research on age-related degenerative diseases, leveraging traditional Chinese medicine (TCM) to address conditions such as osteoporosis, knee osteoarthritis, and Alzheimer's disease, particularly focusing on the concept of kidney deficiency [4][6]. Group 1: Event Overview - The signing ceremony for the clinical research project was held on April 29, organized by Jinan University and attended by various experts and scholars from Guangdong [2]. - Key representatives included Zhang Ronghua, Vice President of Jinan University, and Ma Yun, Deputy General Manager of Zhongjing Wanshi Pharmaceutical, who signed the cooperation agreement [6]. Group 2: Research Focus - The project will explore the pathological mechanisms and key targets of age-related degenerative diseases, emphasizing the role of kidney deficiency in these conditions [6]. - The research aims to innovate TCM applications, particularly the modern use of classic formulas like Zuo Gui Wan and You Gui Wan, in treating kidney deficiency-related diseases [4][6]. Group 3: Collaborative Goals - The collaboration seeks to integrate multidisciplinary approaches to enhance the understanding and treatment of age-related diseases through TCM [6]. - Zhongjing Wanshi Pharmaceutical emphasizes the importance of high-quality medicinal materials and aims to explore new treatment pathways that combine TCM and Western medicine [6].

Core Insights - Tong Ren Tang Guo Yao achieved a revenue of HKD 1.612 billion, representing a year-on-year growth of 5.7%, and a net profit of HKD 529 million for the reporting period [2] Group 1: Business Performance - The company launched several new products, including the NMN anti-aging series and other traditional Chinese medicine products, enhancing its product matrix [3] - Revenue from the Hong Kong market reached HKD 1.07 billion, showing a significant year-on-year increase of 16.9% despite challenges in the retail sector [6] - The company expanded its retail presence in Hong Kong, increasing the number of retail terminals to 29, a net addition of 2 stores compared to the previous year [6] Group 2: Research and Development - Tong Ren Tang Guo Yao strengthened its R&D efforts, achieving significant results in product innovation and safety studies, including the approval of Danggui Blood Supplement Granules [3][4] - The company signed a cooperation agreement with Macau University of Science and Technology to enhance research collaboration and product registration [3] Group 3: Marketing and Brand Promotion - The company actively engaged in marketing activities, including the "Tong Ren Tang Day" and the "9th Tong Ren Care Against Stroke" series, to promote its brand and cultural heritage [5][7] - Tong Ren Tang Guo Yao emphasized its commitment to public welfare as a core aspect of its brand culture, conducting health-related activities in collaboration with local institutions [7] Group 4: Future Outlook - For 2025, the company aims to focus on "adjustment and recovery, cost reduction, and efficiency enhancement," implementing strategies to optimize management, products, investments, and finances [7]